肺がんの早期診断のための血漿プロテオームバイオマーカー
肺がんの早期診断のための血漿プロテオームバイオマーカーの同定と機能検証研究
We will identify plasma proteomics biomarkers for early diagnosis of lung cancer.
調査の概要
状態
条件
詳細な説明
We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients and controls. Artificial intelligent (AI) assisted proteomics classifier will be developed for early diagnosis of lung cancer.
研究の種類
入学 (推定)
連絡先と場所
研究場所
-
-
China
-
Hangzhou、China、中国、310009
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Study group: Patients with suspected or confirmed diagnosis of lung cancer. Control group: Non-cancer subjects including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc.
説明
Inclusion Criteria:
- CT screening results showed that the size of pulmonary nodules was more than 5mm
- No treatment related to pulmonary nodules/lung cancer (including surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, interventional therapy, etc.)
- Complete clinical and imaging data
- Chest CT/ low-dose spiral CT reports can be provided in the last 3 months
- Voluntarily sign informed consent
Exclusion Criteria:
- There is a history of tumor
- Clinically uncontrolled active infections, such as acute pneumonia, tuberculosis, etc.
- Received any treatment related to pulmonary nodules, such as antibiotics and hormones, in the past 4 weeks
- Complicated with other tumors and serious diseases of the heart, liver, kidney, brain, blood and other systems
- Participated in other clinical trials within the last 3 months
- Combined with liver and kidney insufficiency, hypoproteinemia and other diseases affecting protein content
- You are pregnant or breastfeeding
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Lung cancer group
Patients age over 18, with confirmed diagnosis of lung cancer. |
Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients . Plasma samples of control subjects were collected. |
|
Control group
Non-cancer patients including healthy volunteers, chronic inflammatory airway diseases such as chronic obstructive airway disease, asthma, and bronchiectasis, etc. |
Plasma samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment.We will use TMT-based proteomics approaches to analyze more than 2000 proteins in plasma samples from lung cancer patients . Plasma samples of control subjects were collected. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Plasma proteomic biomarkers
時間枠:1 month after surgery
|
Plasma proteomic biomarkers for detection of lung cancer |
1 month after surgery
|
|
Model or classifier performance
時間枠:1 month after surgery
|
Artificial intelligent (AI) assisted proteomics classifier will be developed for early diagnosis of lung cancer; and model or classifier performance including AUC, sensitivity, specificity, and accuracy |
1 month after surgery
|
協力者と研究者
捜査官
- スタディチェア:Weilin Wang、2nd Affiliated Hospital, School of Medicine, Zhejiang University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。